Regulation of histone H2A.Z expression is mediated by sirtuin 1 in prostate cancer

Oncotarget

Volumn 4, Issue 10, 2013, Pages 1673-1685

  Baptista, Tiago ^a   Graça, Inês ^a,b   Sousa, Elsa J ^a   Oliveira, Ana I ^a   Costa, Natália R ^a   Costa Pinheiro, Pedro ^a   Amado, Francisco ^c   Henrique, Rui ^a,d   Jerónimo, Carmen ^a,d  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b POLYTECHNIC INSTITUTE OF PORTO   (Portugal)

^c UNIVERSITY OF AVEIRO   (Portugal)

^d UNIVERSITY OF PORTO   (Portugal)

Author keywords

Epigenetic drugs; H2A.Z; Prostate cancer; Sirtuin 1

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; HISTONE H2AZ; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; NICOTINAMIDE; PROTEASOME; RESVERATROL; SIRTUIN 1; TRICHOSTATIN A;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CARCINOGENESIS; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; EPIGENETICS; H2AZ GENE; HISTONE MODIFICATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIMARY TUMOR; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; SIRTUIN 1 GENE; TRANSCRIPTION REGULATION; UPREGULATION;

AGED; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIRTUIN 1;

EID: 84886743585     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1237     Document Type: Article

References (50)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2012. CA: a cancer journal for clinicians. 2012; 62(1):10-29.
2. Shen MM and Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes & development. 2010; 24(18):1967-2000.
3. Jeronimo C, Bastian PJ, Bjartell A, Carbone GM, Catto JW, Clark SJ, Henrique R, Nelson WG and Shariat SF. Epigenetics in prostate cancer: biologic and clinical relevance. European urology. 2011; 60(4):753-766.
4. Altaf M, Auger A, Covic M and Cote J. Connection between histone H2A variants and chromatin remodeling complexes. Biochemistry and cell biology = Biochimie et biologie cellulaire. 2009; 87(1):35-50.
5. Rangasamy D, Greaves I and Tremethick DJ. RNA interference demonstrates a novel role for H2A.Z in chromosome segregation. Nature structural & molecular biology. 2004; 11(7):650-655.
6. Dhillon N, Oki M, Szyjka SJ, Aparicio OM and Kamakaka RT. H2A.Z functions to regulate progression through the cell cycle. Molecular and cellular biology. 2006; 26(2):489-501.
7. Meneghini MD, Wu M and Madhani HD. Conserved histone variant H2A.Z protects euchromatin from the ectopic spread of silent heterochromatin. Cell. 2003; 112(5):725-736.
8. Dunican DS, McWilliam P, Tighe O, Parle-McDermott A and Croke DT. Gene expression differences between the microsatellite instability (MIN) and chromosomal instability (CIN) phenotypes in colorectal cancer revealed by high-density cDNA array hybridization. Oncogene. 2002; 21(20):3253-3257.
9. Hua S, Kallen CB, Dhar R, Baquero MT, Mason CE, Russell BA, Shah PK, Liu J, Khramtsov A, Tretiakova MS, Krausz TN, Olopade OI, Rimm DL and White KP. Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression. Molecular systems biology. 2008; 4:188.
10. Zucchi I, Mento E, Kuznetsov VA, Scotti M, Valsecchi V, Simionati B, Vicinanza E, Valle G, Pilotti S, Reinbold R, Vezzoni P, Albertini A and Dulbecco R. Gene expression profiles of epithelial cells microscopically isolated from a breast-invasive ductal carcinoma and a nodal metastasis. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101(52):18147-18152.
11. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101(25):9309-9314.
12. Farris SD, Rubio ED, Moon JJ, Gombert WM, Nelson BH and Krumm A. Transcription-induced chromatin remodeling at the c-myc gene involves the local exchange of histone H2A.Z. The Journal of biological chemistry. 2005; 280(26):25298-25303.
13. Marques M, Laflamme L, Gervais AL and Gaudreau L. Reconciling the positive and negative roles of histone H2A.Z in gene transcription. Epigenetics: official journal of the DNA Methylation Society. 2010; 5(4):267-272.
14. Dryhurst D, McMullen B, Fazli L, Rennie PS and Ausio J. Histone H2A.Z prepares the prostate specific antigen (PSA) gene for androgen receptor-mediated transcription and is upregulated in a model of prostate cancer progression. Cancer letters. 2012; 315(1):38-47.
15. Valdes-Mora F, Song JZ, Statham AL, Strbenac D, Robinson MD, Nair SS, Patterson KI, Tremethick DJ, Stirzaker C and Clark SJ. Acetylation of H2A.Z is a key epigenetic modification associated with gene deregulation and epigenetic remodeling in cancer. Genome research. 2012; 22(2):307-321.
16. Chen IY, Lypowy J, Pain J, Sayed D, Grinberg S, Alcendor RR, Sadoshima J and Abdellatif M. Histone H2A.z is essential for cardiac myocyte hypertrophy but opposed by silent information regulator 2alpha. The Journal of biological chemistry. 2006; 281(28):19369-19377.
17. Bosch-Presegue L and Vaquero A. The dual role of sirtuins in cancer. Genes & cancer. 2011; 2(6):648-662.
18. Deng CX. SIRT1, is it a tumor promoter or tumor suppressor? International journal of biological sciences. 2009; 5(2):147-152.
19. Bradbury CA, Khanim FL, Hayden R, Bunce CM, White DA, Drayson MT, Craddock C and Turner BM. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia. 2005; 19(10):1751-1759.
20. Stunkel W, Peh BK, Tan YC, Nayagam VM, Wang X, Salto-Tellez M, Ni B, Entzeroth M and Wood J. Function of the SIRT1 protein deacetylase in cancer. Biotechnology journal. 2007; 2(11):1360-1368.
21. Wang RH, Sengupta K, Li C, Kim HS, Cao L, Xiao C, Kim S, Xu X, Zheng Y, Chilton B, Jia R, Zheng ZM, Appella E, Wang XW, Ried T and Deng CX. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer cell. 2008; 14(4):312-323.
22. Huffman DM, Grizzle WE, Bamman MM, Kim JS, Eltoum IA, Elgavish A and Nagy TR. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer research. 2007; 67(14):6612-6618.
23. Firestein R, Blander G, Michan S, Oberdoerffer P, Ogino S, Campbell J, Bhimavarapu A, Luikenhuis S, de Cabo R, Fuchs C, Hahn WC, Guarente LP and Sinclair DA. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PloS one. 2008; 3(4):e2020.
24. Powell MJ, Casimiro MC, Cordon-Cardo C, He X, Yeow WS, Wang C, McCue PA, McBurney MW and Pestell RG. Disruption of a Sirt1-dependent autophagy checkpoint in the prostate results in prostatic intraepithelial neoplasia lesion formation. Cancer research. 2011; 71(3):964-975.
25. Wang RH, Zheng Y, Kim HS, Xu X, Cao L, Luhasen T, Lee MH, Xiao C, Vassilopoulos A, Chen W, Gardner K, Man YG, Hung MC, Finkel T and Deng CX. Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Molecular cell. 2008; 32(1):11-20.
26. Ghosh HS, McBurney M and Robbins PD. SIRT1 negatively regulates the mammalian target of rapamycin. PloS one. 2010; 5(2):e9199.
27. Rangasamy D. Histone variant H2A.Z can serve as a new target for breast cancer therapy. Current medicinal chemistry. 2010; 17(28):3155-3161.
28. Svotelis A, Gevry N, Grondin G and Gaudreau L. H2A.Z overexpression promotes cellular proliferation of breast cancer cells. Cell Cycle. 2010; 9(2):364-370.
29. Fusco S, Maulucci G and Pani G. Sirt1: def-eating senescence? Cell Cycle. 2012; 11(22):4135-4146.
30. Chen W. Accelerating cancer evolution: a dark side of SIRT1 in genome maintenance. Oncotarget. 2012; 3(4):363-364.
31. Wang Z, Yuan H, Roth M, Stark JM, Bhatia R and Chen WY. SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells. Oncogene. 2013; 32(5):589-598.
32. Brooks CL and Gu W. p53 Activation: a case against Sir. Cancer cell. 2008; 13(5):377-378.
33. Nemoto S, Fergusson MM and Finkel T. Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Science. 2004; 306(5704):2105-2108.
34. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C and Abate-Shen C. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. The Journal of clinical investigation. 2008; 118(9):3051-3064.
35. Kremer CL, Klein RR, Mendelson J, Browne W, Samadzedeh LK, Vanpatten K, Highstrom L, Pestano GA and Nagle RB. Expression of mTOR signaling pathway markers in prostate cancer progression. The Prostate. 2006; 66(11):1203-1212.
36. Halley JE, Kaplan T, Wang AY, Kobor MS and Rine J. Roles for H2A.Z and its acetylation in GAL1 transcription and gene induction, but not GAL1-transcriptional memory. PLoS biology. 2010; 8(6):e1000401.
37. Bruce K, Myers FA, Mantouvalou E, Lefevre P, Greaves I, Bonifer C, Tremethick DJ, Thorne AW and Crane-Robinson C. The replacement histone H2A.Z in a hyperacetylated form is a feature of active genes in the chicken. Nucleic acids research. 2005; 33(17):5633-5639.
38. Audrito V, Vaisitti T, Rossi D, Gottardi D, D'Arena G, Laurenti L, Gaidano G, Malavasi F and Deaglio S. Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network. Cancer research. 2011; 71(13):4473-4483.
39. Nakayama H, Yaguchi T, Yoshiya S and Nishizaki T. Resveratrol induces apoptosis MH7A human rheumatoid arthritis synovial cells in a sirtuin 1-dependent manner. Rheumatology international. 2012; 32(1):151-157.
40. Wong MM, Cox LK and Chrivia JC. The chromatin remodeling protein, SRCAP, is critical for deposition of the histone variant H2A.Z at promoters. The Journal of biological chemistry. 2007; 282(36):26132-26139.
41. Yang X, Noushmehr H, Han H, Andreu-Vieyra C, Liang G and Jones PA. Gene reactivation by 5-aza-2'-deoxycytidine-induced demethylation requires SRCAP-mediated H2A.Z insertion to establish nucleosome depleted regions. PLoS genetics. 2012; 8(3):e1002604.
42. Slupianek A, Yerrum S, Safadi FF and Monroy MA. The chromatin remodeling factor SRCAP modulates expression of prostate specific antigen and cellular proliferation in prostate cancer cells. Journal of cellular physiology. 2010; 224(2):369-375.
43. Halkidou K, Gnanapragasam VJ, Mehta PB, Logan IR, Brady ME, Cook S, Leung HY, Neal DE and Robson CN. Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene. 2003; 22(16):2466-2477.
44. Hawksworth D, Ravindranath L, Chen Y, Furusato B, Sesterhenn IA, McLeod DG, Srivastava S and Petrovics G. Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence. Prostate cancer and prostatic diseases. 2010; 13(4):311-315.
45. Prochownik EV and Vogt PK. Therapeutic Targeting of Myc. Genes & cancer. 2010; 1(6):650-659.
46. Kriegl L, Vieth M, Kirchner T and Menssen A. Up-regulation of c-MYC and SIRT1 expression correlates with malignant transformation in the serrated route to colorectal cancer. Oncotarget. 2012; 3(10):1182-1193.
47. Mao B, Zhao G, Lv X, Chen HZ, Xue Z, Yang B, Liu DP and Liang CC. Sirt1 deacetylates c-Myc and promotes c-Myc/Max association. The international journal of biochemistry & cell biology. 2011; 43(11):1573-1581.
48. Menssen A and Hermeking H. c-MYC and SIRT1 locked in a vicious cycle. Oncotarget. 2012; 3(2):112-113.
49. Menssen A, Hydbring P, Kapelle K, Vervoorts J, Diebold J, Luscher B, Larsson LG and Hermeking H. The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109(4):E187-196.
50. Yuan J, Minter-Dykhouse K and Lou Z. A c-Myc-SIRT1 feedback loop regulates cell growth and transformation. The Journal of cell biology. 2009; 185(2):203-211.